Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Settle Terms Before Brexit Divorce Is Final, Former EMA Chief Says

Executive Summary

If the European Medicines Agency has to desert London as a result of the UK’s decision to leave the EU, it will have to take care in managing issues such as the loss of expert input from the UK regulator, the MHRA, says former EMA head Thomas Lönngren.


Related Content

Brexit: EMA To Bolster Regulatory Reserves Ahead Of Relocation
Japan Wants EMA To Stay In UK Post-Brexit
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
Brain Drain And Recruitment Risks for EMA post UK Brexit Vote
Brexit Highlights Strong British Presence In EU Medicines Network





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst